The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

摘要: To date, there is an increasing interest in the nitric oxide (NO) pathway as a potential pharmacological target to treat male lower urinary tract symptomatology (LUTS). In transition zone of human prostate, dense nitrinergic innervation has been shown fibromuscular stroma, glandular epithelium and blood vessels. The expression key proteins NO pathway, such endothelial neuronal synthase (eNOS, nNOS), cGMP-degrading phosphodiesterase type 5 (PDE5) cGMP-binding protein kinase (cGK), also demonstrated. hypothesis that impaired NO/cGMP-signaling may contribute pathophysiology benign prostatic hyperplasia (BPH) supported by results from randomized, placebo-controlled clinical studies, indicating donor drugs PDE5-inhibitors sildenafil, tadalafil vardenafil be useful storage voiding dysfunctions resulting LUTS men. Thus, given role NO-pathway prostate and/or other parts (e.g. bladder), enhancement signaling drugs, PDE5 inhibitors or activators soluble guanylyl cyclase (sGC) represent new therapeutic strategy for treatment LUTS. This review serves focus on NO-dependent control smooth muscle function prostate. Results trials men with LUTS/BPH are discussed.